CINGW

Cingulate (CINGW)

Cingulate Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:CINGW

1 2 3 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/21	22:00	GlobeNewswire Inc.	FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD	NASDAQ:CINGW	Cingulate Inc
2024/05/18	06:01	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:CINGW	Cingulate Inc
2024/05/13	21:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CINGW	Cingulate Inc
2024/05/08	20:15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CINGW	Cingulate Inc
2024/05/08	20:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CINGW	Cingulate Inc
2024/05/08	20:00	GlobeNewswire Inc.	Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update	NASDAQ:CINGW	Cingulate Inc
2024/04/30	18:45	GlobeNewswire Inc.	Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access	NASDAQ:CINGW	Cingulate Inc
2024/04/17	06:00	GlobeNewswire Inc.	Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024	NASDAQ:CINGW	Cingulate Inc
2024/04/01	21:00	GlobeNewswire Inc.	Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update	NASDAQ:CINGW	Cingulate Inc
2024/03/20	05:45	GlobeNewswire Inc.	Cingulate to Participate in Benzinga All Live Access Event	NASDAQ:CINGW	Cingulate Inc
2024/03/06	20:45	GlobeNewswire Inc.	Cingulate to Attend DCAT Week 2024 in New York City	NASDAQ:CINGW	Cingulate Inc
2024/02/13	20:45	GlobeNewswire Inc.	Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors	NASDAQ:CINGW	Cingulate Inc
2024/02/07	06:15	GlobeNewswire Inc.	Cingulate Announces Closing of $7.5 Million Public Offering	NASDAQ:CINGW	Cingulate Inc
2024/02/02	23:15	GlobeNewswire Inc.	Cingulate Announces Pricing of $7.5 Million Public Offering	NASDAQ:CINGW	Cingulate Inc
2024/01/29	22:00	GlobeNewswire Inc.	Longtime Cingulate Controller Jennifer Callahan Promoted to CFO	NASDAQ:CINGW	Cingulate Inc
2024/01/29	20:45	GlobeNewswire Inc.	Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market	NASDAQ:CINGW	Cingulate Inc
2023/12/01	23:00	GlobeNewswire Inc.	Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)	NASDAQ:CINGW	Cingulate Inc
2023/11/14	06:15	GlobeNewswire Inc.	Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update	NASDAQ:CINGW	Cingulate Inc
2023/10/18	03:22	GlobeNewswire Inc.	Cingulate to Host CNS Key Opinion Leader Panel in New York City	NASDAQ:CINGW	Cingulate Inc
2023/09/22	02:30	GlobeNewswire Inc.	Cingulate Inc. to Present at the LD Micro Main Event XVI	NASDAQ:CINGW	Cingulate Inc
2023/09/14	05:15	GlobeNewswire Inc.	Cingulate Announces Closing of $4.0 Million Public Offering	NASDAQ:CINGW	Cingulate Inc
2023/09/11	22:22	GlobeNewswire Inc.	Cingulate Announces Pricing of $4.0 Million Public Offering	NASDAQ:CINGW	Cingulate Inc
2023/09/11	19:00	GlobeNewswire Inc.	Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD	NASDAQ:CINGW	Cingulate Inc
2023/09/09	05:31	GlobeNewswire Inc.	Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium	NASDAQ:CINGW	Cingulate Inc
2023/09/05	21:00	GlobeNewswire Inc.	Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023	NASDAQ:CINGW	Cingulate Inc
2023/08/15	05:15	GlobeNewswire Inc.	Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update	NASDAQ:CINGW	Cingulate Inc
2023/07/11	21:00	GlobeNewswire Inc.	Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD	NASDAQ:CINGW	Cingulate Inc
2023/06/29	21:00	GlobeNewswire Inc.	Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August	NASDAQ:CINGW	Cingulate Inc
2023/06/15	04:45	GlobeNewswire Inc.	Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest	NASDAQ:CINGW	Cingulate Inc
2023/06/08	20:00	GlobeNewswire Inc.	Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD	NASDAQ:CINGW	Cingulate Inc